|1.||Dutartre, P: 2 articles (01/2002 - 01/2001)|
|2.||Gluckman, E: 2 articles (01/2002 - 01/2001)|
|3.||Behar-Cohen, Francine: 1 article (07/2011)|
|4.||Camelo, Serge: 1 article (07/2011)|
|5.||Naud, Marie-Christine: 1 article (07/2011)|
|6.||Besson-Lescure, Bernadette: 1 article (07/2011)|
|7.||Annat, Jocelyne: 1 article (07/2011)|
|8.||Leroux les Jardins, Guillaume: 1 article (07/2011)|
|9.||Goldenberg, Brigitte: 1 article (07/2011)|
|10.||Bousquet, Elodie: 1 article (07/2011)|
|1.||Graft vs Host Disease (Graft-Versus-Host Disease)
07/01/2001 - "Tresperimus shows promise in the move from immunosuppression to tolerance induction as the way to prevent transplant rejection and graft versus host disease (G v HD). "
01/01/2001 - "These results may be of clinical interest as tresperimus is currently used in phase I-III studies for the prevention of graft versus host disease in recipients of allogeneic bone marrow."
01/01/2002 - "Bearing in mind that the test drug supports the clonogenic potential of CD34+ cells, the overall findings emphasize the importance of assessing the effect of tresperimus on in vivo long-term hematopoiesis which could predict the potential clinical use of tresperimus in the prevention of graft-versus-host disease in recipients of allogeneic bone marrow."
09/27/1996 - "We investigated the ability of LF 08--0299, a new immunosuppressive compound, to prevent murine graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT). "
09/27/1996 - "Prevention of lethal graft-versus-host disease following allogeneic bone marrow transplantation in mice by short course administration of LF 08-0299."
|2.||LF 08-0299 (tresperimus)
|1.||Bone Marrow Transplantation (Transplantation, Bone Marrow)